145 results
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 May 24
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
9:00am
"expanded access" program completed five years of successful treatment. The patient remains cancer-free and reported no significant safety
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
to be presented at the AACR Annual Meeting – safety and efficacy data from the 40mg pharmacokinetic run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen
8-K
EX-99.1
202taf
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
8-K
pr8c17rutb6e frsfrjq
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
8-K
EX-99.1
9e3yx2jaat2h3tf
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
8-K
EX-99.1
ehhqt56klqp yjdo
15 May 23
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:10am
8-K
EX-99.1
vwmft3qmk
7 Nov 22
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
EX-99.1
riw 63rqr
8 Aug 22
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
6jf6vp3 9x9
6 Jun 22
Regulation FD Disclosure
2:45pm
8-K
EX-99.1
0doe1q hwvgd
9 May 22
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
4:00pm